Randomized phase III trial of Docetaxel versus docetaxel plus S-1 for second-line treatment of non-small cell lung cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 09 May 2017
At a glance
- Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Apr 2009 New trial record.